CN117343206A - Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs - Google Patents
Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs Download PDFInfo
- Publication number
- CN117343206A CN117343206A CN202311311426.4A CN202311311426A CN117343206A CN 117343206 A CN117343206 A CN 117343206A CN 202311311426 A CN202311311426 A CN 202311311426A CN 117343206 A CN117343206 A CN 117343206A
- Authority
- CN
- China
- Prior art keywords
- inflammatory
- fucoidin
- supernatant
- preparation
- concentrated solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 229940124599 anti-inflammatory drug Drugs 0.000 title claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 13
- 239000002244 precipitate Substances 0.000 claims abstract description 13
- 241001261506 Undaria pinnatifida Species 0.000 claims abstract description 11
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 9
- 239000005017 polysaccharide Substances 0.000 claims abstract description 9
- 102000003814 Interleukin-10 Human genes 0.000 claims abstract description 8
- 108090000174 Interleukin-10 Proteins 0.000 claims abstract description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims abstract description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 8
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 claims abstract description 7
- 108090000193 Interleukin-1 beta Proteins 0.000 claims abstract description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 7
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract description 7
- 108010043603 integrin alpha4beta7 Proteins 0.000 claims abstract description 5
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 22
- 239000006228 supernatant Substances 0.000 claims description 22
- 229920000855 Fucoidan Polymers 0.000 claims description 20
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 14
- 238000000502 dialysis Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 210000001986 peyer's patch Anatomy 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 5
- 229940072056 alginate Drugs 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 238000003760 magnetic stirring Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000012044 organic layer Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims description 2
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 229940076144 interleukin-10 Drugs 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 238000003260 vortexing Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 abstract description 12
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 5
- 102100037850 Interferon gamma Human genes 0.000 abstract description 5
- 230000000770 proinflammatory effect Effects 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract 2
- 241001480978 Pyropia haitanensis Species 0.000 abstract 1
- 239000000706 filtrate Substances 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 9
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 8
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 7
- 210000002865 immune cell Anatomy 0.000 description 6
- 210000004400 mucous membrane Anatomy 0.000 description 6
- 230000028993 immune response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000007646 directional migration Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- -1 polysaccharide compound Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000195480 Fucus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Sustainable Development (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of biochemistry, and particularly discloses a preparation method of fucoidin and application of the fucoidin in preparation of anti-inflammatory drugs. The preparation method comprises the following steps: pulverizing Undaria pinnatifida, extracting with water, filtering, adding ethanol into the filtrate, standing, filtering again, adding water into the precipitate, and lyophilizing to obtain Porphyra haitanensis crude polysaccharide. The fucoidin prepared by the invention is a functional polysaccharide, and can reduce the expression of Integrin alpha 4 beta 7 (Intergrin alpha 4 beta 7) and mucosa address adhesion molecule 1 (MAdCAM-1) in the Petri's junction. Meanwhile, the anti-inflammatory agent also has the effects of reducing the levels of pro-inflammatory factors IFN-gamma, TNF-alpha, IL-1 beta and IL-6 and improving the levels of anti-inflammatory factors IL-10 and TGF-beta.
Description
Technical Field
The invention relates to the technical field of biochemistry, in particular to a preparation method of fucoidin and application of the fucoidin in preparation of anti-inflammatory drugs.
Background
Peyer's patch is a lymphoid structure located below the intestinal mucosa and is formed by the aggregation of B cells. It is an important component of the intestinal mucosal immune system, mainly involved in regulating the intestinal immune response and maintaining mucosal barrier function. B cells in the peyer's patch can differentiate into transformation center B cells, helper B cells, plasma cells, and the like.
When the mucous membrane of the small intestine is infected or otherwise irritated, the peyer's patch becomes one of the important sites of inflammatory response. Immune cells are activated in the peyer's patch, beginning to release inflammatory factors, such as cytokines and chemokines, to attract more immune cells to the site of inflammation. These immune cells can clear pathogens, repair damaged tissue, and regulate the process of immune responses.
Polysaccharides can regulate the function of the immune system, including promoting activation of immune cells and enhancing immune responses. There are a variety of immune cells in the peyer's patch, such as lymphocytes, dendritic cells, etc., which are critical for the recognition and protection of invading pathogens. Part of the polysaccharide component is thought to stimulate immune cells in the peyer's patch, enhancing their immune function and thus increasing the defenses against pathogens.
Fucoidan is a natural polysaccharide compound extracted from fucus. Fucoidan, a brown algae plant that is mainly present in the ocean, is considered as a bioactive ingredient. Its chemical structure is composed of various sugar molecules, such as glucose, mannose, galactose, glucosamine, etc., and usually contains a sulfate group. Fucoidan has an α -1, 3-backbone or is composed of repeating units consisting of α -1,3 linked fucose and α -1,4 linked fucose disaccharides, branching is linked at the C2 position and sulfation occurs mainly at the O-2 position.
Fucoidan has been attracting attention due to its unique chemical composition and biological activity. Some researches show that fucoidan has various biological activities such as antioxidation, anti-tumor, antivirus and the like, but the influence of fucoidan on immune homing effect in peyer's patch and the application of fucoidan in anti-inflammatory have not been reported yet.
Disclosure of Invention
The invention aims to provide a preparation method of fucoidin and application of the fucoidin in preparation of anti-inflammatory drugs, which can reduce the levels of pro-inflammatory factors IFN-gamma, TNF-alpha, IL-1 beta and IL-6 and improve the levels of anti-inflammatory factors IL-10 and TGF-beta, and has anti-inflammatory effect.
The technical aim of the invention is realized by the following technical scheme:
a method for preparing fucoidin, comprising the following steps:
s1, crushing undaria pinnatifida by using a crusher, and keeping undaria pinnatifida powder for later use;
s2, weighing undaria pinnatifida powder in a beaker, adding distilled water, uniformly stirring with a glass rod, putting a rotor into the beaker, putting the beaker into a constant-temperature magnetic stirring pot, leaching with hot water, extracting by an ultrasonic auxiliary extraction technology, and centrifuging an extracting solution to obtain a supernatant;
s3, placing the supernatant into a rotary steaming instrument to obtain concentrated solution, mixing 3% CaCl2.2H2O with the concentrated solution, placing the mixture in a refrigerator for standing overnight to enable the alginate to be completely precipitated, centrifuging to remove the alginate precipitate in the crude polysaccharide, and taking the supernatant;
s4, mixing the supernatant with absolute ethyl alcohol, standing for precipitation, and centrifuging to obtain a precipitate;
s5, washing the precipitate with absolute ethyl alcohol for 2 times, and then adding water until the precipitate is dissolved to obtain a solution;
s6, performing rotary evaporation on the dissolution liquid to obtain concentrated liquid;
s7, mixing the concentrated solution with a sevage reagent, oscillating by a vortex meter, standing for layering, and taking supernatant;
and S8, placing the supernatant in a refrigerator for dialysis, and drying the supernatant by using a vacuum freeze dryer to obtain the fucoidin.
Further preferably, in step S2, the mass ratio of the undaria pinnatifida to the water is 1:30; the hot water leaching temperature is 80 ℃ and the time is 3.5h; the ultrasonic auxiliary extraction time is 30min; the centrifugal rotating speed is 4000r/min, and the centrifugal time is 10min.
Further preferably, in the step S3, the volume of the concentrated solution is 250mL, the ratio of CaCl2.2H2O to the concentrated solution is 1:1, and the standing overnight temperature is 4 ℃; the centrifugal rotating speed is 3000r/min, and the time is 20min.
Further preferably, the volume ratio of the supernatant to the absolute ethanol in the step S4 is 1:4, and the final concentration is 80%; the sedimentation time is 12h, the centrifugal rotating speed is 4000r/min, and the centrifugal time is 10min.
Further preferably, in the step S7, the volume ratio of the concentrated solution to the sevage reagent is 6:1, and the preparation ratio of the sevage reagent is as follows: chloroform: n-butanol=4:1=v: V, the vortexing time was 20min, and the layering was aqueous layer-denatured protein layer-organic layer with liquid from top to bottom.
It is further preferred that the dialysis in step S8 is performed using a dialysis membrane having a molecular weight cut-off of 10-15kDa, the dialysis temperature in a refrigerator is 4 ℃ and the time is 24 hours, and the number of distilled water changes during the dialysis is 2, wherein the first change is after 4 hours and the second change is after 8 hours.
The invention also provides an application of the fucoidin in preparing anti-inflammatory drugs.
Further preferably, the anti-inflammatory includes anti-inflammatory bowel disease.
Further preferred, the anti-inflammatory bowel disease comprises decreasing the expression of integrin α4β7 and mucoadhesive molecule 1 in the peyer's patch and modulating inflammatory factor levels.
Further preferred, the inflammatory factors include transforming growth factor-beta, interferon-gamma, tumor necrosis factor-alpha, interleukin-1 beta, interleukin-10, and interleukin-6.
Compared with the prior art, the invention has the following beneficial effects:
the fucoidin prepared by the invention is a functional polysaccharide, can regulate the immune homing effect in the Petri junction, and reduces the expression of integrin alpha 4 beta 7 and mucosa address adhesion molecule 1 in the Petri junction. Meanwhile, the anti-inflammatory agent also has the effects of reducing the levels of pro-inflammatory factors IFN-gamma, TNF-alpha, IL-1 beta and IL-6 and improving the levels of anti-inflammatory factors IL-10 and TGF-beta. Can provide theoretical basis for protecting and repairing the damage of fucoidin in intestinal barrier.
Drawings
FIG. 1 is a graph showing the effect of ELISA on the levels of inflammatory factors in mice with DSS-induced colon inflammation;
FIG. 2 is a schematic representation of the interaction of Intigrin α4β7 and MAdCAM-1 in the Petri junction to promote the directional migration and colonization of B cells in mucosal tissue;
FIG. 3 is a graph showing the effect of fucoidan on expression of Intigrin α4β7 and MAdCAM-1 in Petri knots.
Detailed Description
The present invention will be described in further detail with reference to examples for better understanding of the technical aspects of the present invention by those skilled in the art. It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention.
Example 1
Example 1 is the preparation of fucoidan comprising the steps of:
s1, drying undaria pinnatifida and then crushing;
s2, placing the undaria pinnatifida powder prepared in the step S1 into a 1L beaker, adding 30 times of distilled water, uniformly stirring by using a glass rod, placing a rotor into the beaker, placing the beaker into a constant-temperature magnetic stirring pot, and leaching by using 80 ℃ hot water for 3.5h. Extracting with ultrasonic auxiliary extraction technology for 30min, centrifuging the extractive solution at 4000rpm for 10min to obtain supernatant;
s3, placing the supernatant obtained in the step S2 into a rotary steaming instrument for concentration to 250mL, mixing 3% CaCl2.2H2O with the concentrated solution according to the ratio of 1:1, placing the mixture in a refrigerator at the temperature of 4 ℃ for standing overnight, and removing alginate precipitate in crude polysaccharide to obtain supernatant;
s4, mixing the supernatant obtained in the step S3 with absolute ethyl alcohol according to a volume ratio of 1:4, precipitating for 12 hours, and centrifuging for 10 minutes at 4000rpm to obtain a precipitate;
s5, washing the precipitate prepared in the step S4 with absolute ethyl alcohol for 2 times, and adding water until the precipitate is dissolved to obtain a dissolving solution;
s6, performing rotary evaporation on the obtained solution to obtain concentrated solution;
s7, mixing the concentrated solution and sevage reagent (chloroform: n-butanol=4:1=V: V) in a ratio of 6:1, oscillating for 20min by a vortex meter, standing for layering, taking supernatant from top to bottom, wherein the liquid is a water layer, a denatured protein layer and an organic layer;
s8, placing the concentrated solution prepared in the step S7 in a dialysis bag with the specification of 10-15kDa, dialyzing for 24 hours in a refrigerator at the temperature of 4 ℃, and drying the concentrated solution by using a vacuum freeze dryer to obtain the fucoidin of the embodiment.
Example 2
Example 2 is an ELISA assay to examine the effect of fucoidan on inflammatory factor levels in DSS-induced inflammatory bowel disease mice.
Using the fucoidan prepared in example 1, DSS-induced inflammatory bowel disease mice were assayed for inflammatory factor levels, one of which was a blank control group (NC, n=5) and the other was a DSS-induced inflammatory bowel disease model group (IBD, n=15). NC mice received only water as treatment, whereas the inflammatory bowel disease model was induced with 3% dss (w/v) in drinking water.
Inflammatory bowel disease model groups (IBD) were randomized into three groups (n=5) 7 days after DSS induction. These groups included model group (DSS), fucan-treated model group (dss+fuc), and fructo-oligosaccharide-treated model group (dss+fos). The dss+fuc group and the dss+fuc group were given 100mg/kg doses of FUC and FOS, respectively, for 7 consecutive days, while the DSS group was given a conventional diet similar to that of the NC group. Mice were sacrificed on day 22.
To detect the level of inflammatory factors, we anesthetized mice and removed the eyeballs for blood collection. After allowing the blood to coagulate for 30min at room temperature, it was centrifuged (4 ℃,3000rpm,15 min) and the supernatant in the centrifuge tube was collected. The levels of inflammatory factors TNF-alpha, IFN-gamma, IL-1 beta, IL-6, IL-10 and TGF-beta were measured separately using ELISA kits, all reagents and gradient diluted standards were prepared, and 300. Mu.L of 1 Xwash solution was added to an ELISA plate and allowed to stand for 30 seconds. 100. Mu.L of gradient diluted standard was added to the standard wells, 100. Mu.L of standard diluent was added to the blank wells, and 90. Mu.L of 1 Xdetection buffer and 10. Mu.L of sample were added to the sample wells. 50 μl of the corresponding detection antibody diluted 1:100 was added to each well, the membrane was sealed, incubated for 1.5 hours at room temperature, and washed 6 times. 100. Mu.L of 1:100 diluted horseradish peroxidase-labeled streptavidin was added to each well, membrane-sealed, incubated at room temperature for 45 minutes, washed 6 times, then 100. Mu.L of chromogenic substrate was added to each well, incubated at room temperature for 30 minutes in the absence of light, and 100. Mu.L of stop solution was added. The OD value was measured at a wavelength of 450nm using a microplate reader, with 570nm as the reference wavelength.
FIG. 1 is a graph showing the effect of fucoidan on the levels of inflammatory factors in mice with DSS-induced colon inflammation, wherein the abscissa NC, DSS, FUC, FOS is the blank, model, fucoidan-treated, and fructooligosaccharides-treated groups, respectively; the ordinate indicates the concentration of inflammatory factor (pg/ml). As can be seen from fig. 1, in the FUC experimental group, under the repair effect of fucoidan, the levels of IL-10 and TGF- β inflammatory factors secreted by the DSS-induced colon inflammatory mice are significantly improved compared with those of the DSS group, even higher than that of the blank control group (NC), and therefore fucoidan can effectively promote the increase of the levels of anti-inflammatory factors in vivo. Under the restoration effect of fucoidan, the levels of IFN-gamma, TNF-alpha, IL-6 and IL-1 beta inflammatory factors secreted by the DSS-induced colon inflammatory mice in the FUC experimental group are obviously reduced compared with those of the DSS group, even the levels of inflammatory factors in the control group are equal to those of the control group, so that the fucoidan can effectively reduce the levels of pro-inflammatory factors in the colon inflammatory mice.
Example 3
Example 3 determination of the Effect of fucoidan on the immune homing effect in Petri's junction by immunohistochemical method
As shown in FIG. 2, integrin α4β7 is a cell surface receptor capable of binding to the adhesion molecule MAdCAM-1. MAdCAM-1 is widely expressed on the endothelial cell surface of mucosal tissue. When the intersgrinα4β7 on the surface of B cells binds to MAdCAM-1, it promotes directional migration and colonization of B cells in mucosal tissue. Through the interaction of Intigrinα4β7 and MAdCAM-1, B cells can be selectively localized in the intestinal mucosa, which is important for secretory immunoglobulin A to maintain mucosal immune balance. The interaction of inters α4β7 and MAdCAM-1 is also involved in regulating B-cell immune responses in mucosal tissues, including inflammatory regulatory functions. During the development of inflammatory bowel disease, inflammatory signals may drive the production of inflammatory cytokines and chemokines by mucosal tissues, such as: IL6, IL-10, TGF-beta, etc., which can increase the expression of Intigrin alpha 4 beta 7 and MAdCAM-1.
Using the DSS-induced inflammatory bowel disease mouse model of example 2, the mice were sacrificed and dissected. The Petri knots were isolated from the small intestine, fixed with 4% paraformaldehyde for 24 hours, and then embedded in paraffin to make sections. The sections were immersed in two varying xylenes for 15 minutes each. The sections were soaked in 100%, 95%, 85% and 70% ethanol for 5 minutes, respectively. Prepared with water, 3% h2o2, and the sections were placed in solution and incubated for 20min at room temperature. The tissue was blocked by dropping 10% goat serum, incubated at 37℃for 30min, and then incubated with antibodies Intigrin. Alpha.4β7 (1:200,Santa Cruz,United States) and MAdCAM-1 (1:400,Santa Cruz,United States) at 37℃for 2 hours, respectively. Slides were washed with PBST and incubated with HRP-labeled secondary antibody. After rinsing with PBST, the sections were incubated with DAB (3, 30-diaminobenzidine) for visualization. DAB working solution is dripped on the tissue, the glass slide is placed under a microscope for observation, and the DAB chromogenic solution on the tissue is rinsed with water when specific brown expression occurs. Subsequently, the slides were washed in tap water, stained with harris hematoxylin, dehydrated with ethanol, coverslips were covered on the tissue, and air dried.
As shown in fig. 3, the expression of DSS group intelgrinα4β7 and MAdCAM-1 was significantly increased (p < 0.5) compared to the blank and experimental groups, and both were higher than the experimental group. It is shown that fucoidin can reduce the expression of Intigrin alpha 4 beta 7 and MAdCAM-1, slow down the immune response of inflammatory cytokines and chemokines generated in Petri's junction, and effectively improve the inflammatory bowel disease of mice.
The present embodiment is only for explanation of the present invention and is not to be construed as limiting the present invention, and modifications to the present embodiment, which may not creatively contribute to the present invention as required by those skilled in the art after reading the present specification, are all protected by patent laws within the scope of claims of the present invention.
Claims (10)
1. A method for preparing fucoidin, which is characterized by comprising the following steps:
s1, crushing undaria pinnatifida by using a crusher, and keeping undaria pinnatifida powder for later use;
s2, weighing undaria pinnatifida powder in a beaker, adding distilled water, uniformly stirring with a glass rod, putting a rotor into the beaker, putting the beaker into a constant-temperature magnetic stirring pot, leaching with hot water, extracting by an ultrasonic auxiliary extraction technology, and centrifuging an extracting solution to obtain a supernatant;
s3, placing the supernatant into a rotary steaming instrument to obtain concentrated solution, mixing 3% CaCl2.2H2O with the concentrated solution, placing the mixture in a refrigerator for standing overnight to enable the alginate to be completely precipitated, centrifuging to remove the alginate precipitate in the crude polysaccharide, and taking the supernatant;
s4, mixing the supernatant with absolute ethyl alcohol, standing for precipitation, and centrifuging to obtain a precipitate;
s5, washing the precipitate with absolute ethyl alcohol for 2 times, and then adding water until the precipitate is dissolved to obtain a solution;
s6, performing rotary evaporation on the dissolution liquid to obtain concentrated liquid;
s7, mixing the concentrated solution with a sevage reagent, oscillating by a vortex meter, standing for layering, and taking supernatant;
and S8, placing the supernatant in a refrigerator for dialysis, and drying the supernatant by using a vacuum freeze dryer to obtain the fucoidin.
2. The method according to claim 1, wherein in the step S2, the mass ratio of the undaria pinnatifida to the water is 1:30; the hot water leaching temperature is 80 ℃ and the time is 3.5h; the ultrasonic auxiliary extraction time is 30min; the centrifugal rotating speed is 4000r/min, and the centrifugal time is 10min.
3. The method for preparing fucoidin according to claim 1, wherein in the step S3, the volume of the concentrated solution is 250mL, the ratio of cacl2.2h2o to the concentrated solution is 1:1, and the standing overnight temperature is 4 ℃; the centrifugal rotating speed is 3000r/min, and the time is 20min.
4. The method for preparing fucoidin according to claim 1, wherein the volume ratio of supernatant to absolute ethanol in the step S4 is 1:4, and the final concentration is 80%; the sedimentation time is 12h, the centrifugal rotating speed is 4000r/min, and the centrifugal time is 10min.
5. The method for preparing fucoidin according to claim 1, wherein the volume ratio of the concentrated solution to the sevage reagent in the step S7 is 6:1, and the formulation ratio of the sevage reagent is: chloroform: n-butanol=4:1=v: V, the vortexing time was 20min, and the layering was aqueous layer-denatured protein layer-organic layer with liquid from top to bottom.
6. The method according to claim 1, wherein the dialysis membrane with a molecular weight cut-off of 10-15kDa is used in the dialysis in the step S8, the dialysis temperature is 4 ℃ in a refrigerator, the time is 24 hours, and the number of distilled water changes during the dialysis is 2, wherein the first change is after 4 hours and the second change is after 8 hours.
7. Use of a fucoidin according to any one of claims 1-6 for the preparation of an anti-inflammatory drug.
8. Use of a fucan according to claim 7 for the preparation of an anti-inflammatory medicament, wherein the anti-inflammatory comprises anti-inflammatory bowel disease.
9. The use of fucoidan according to claim 8 for the preparation of an anti-inflammatory agent, wherein said anti-inflammatory bowel disease comprises decreasing the expression of integrin α4β7 and mucoaddress adhesion molecule 1 in the peyer's patch and modulating inflammatory factor levels.
10. The use of fucoidan according to claim 9 for the preparation of anti-inflammatory drugs, wherein said inflammatory factors comprise transforming growth factor- β, interferon- γ, tumor necrosis factor- α, interleukin-1 β, interleukin-10 and interleukin-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311426.4A CN117343206A (en) | 2023-10-11 | 2023-10-11 | Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311311426.4A CN117343206A (en) | 2023-10-11 | 2023-10-11 | Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117343206A true CN117343206A (en) | 2024-01-05 |
Family
ID=89360647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311311426.4A Pending CN117343206A (en) | 2023-10-11 | 2023-10-11 | Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117343206A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109734820A (en) * | 2018-11-22 | 2019-05-10 | 浙江工业大学 | A kind of preparation method of small molecule fucoidin |
| CN115028750A (en) * | 2022-06-09 | 2022-09-09 | 泸州品创科技有限公司 | Ascophyllum nodosum fucoidin and preparation method and application thereof |
| CN115414380A (en) * | 2022-09-06 | 2022-12-02 | 广东海洋大学 | Preparation method of porphyra haitanensis oligosaccharide and application of porphyra haitanensis oligosaccharide in preparation of anti-inflammatory drugs |
| CN115490780A (en) * | 2022-10-12 | 2022-12-20 | 广东海洋大学 | Extraction method and application of crude extract of gulfweed fucoidin |
-
2023
- 2023-10-11 CN CN202311311426.4A patent/CN117343206A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109734820A (en) * | 2018-11-22 | 2019-05-10 | 浙江工业大学 | A kind of preparation method of small molecule fucoidin |
| CN115028750A (en) * | 2022-06-09 | 2022-09-09 | 泸州品创科技有限公司 | Ascophyllum nodosum fucoidin and preparation method and application thereof |
| CN115414380A (en) * | 2022-09-06 | 2022-12-02 | 广东海洋大学 | Preparation method of porphyra haitanensis oligosaccharide and application of porphyra haitanensis oligosaccharide in preparation of anti-inflammatory drugs |
| CN115490780A (en) * | 2022-10-12 | 2022-12-20 | 广东海洋大学 | Extraction method and application of crude extract of gulfweed fucoidin |
Non-Patent Citations (8)
| Title |
|---|
| PREPARATION METHODS, BIOLOGICAL ACTIVITIES, AND POTENTIAL APPLICATIONS OF MARINE ALGAE OLIGOSACCHARIDES: A REVIEWLIXIN ZHENG等: "Preparation methods, biological activities, and potential applications of marine algae oligosaccharides: a review", 《FOOD SCIENCE AND HUMAN WELLNESS》, 15 August 2022 (2022-08-15) * |
| 刘一鹿;方月妮;钱强;: "裙带菜多糖提取方法及其功用研究概述", 大家健康(学术版), no. 04, 28 February 2013 (2013-02-28), pages 12 * |
| 刘颖;张敏;吴茜茜;潘仁瑞;蔡敬民;: "岩藻多糖的研究进展", 食品与发酵工业, no. 06, 30 June 2011 (2011-06-30) * |
| 孙占一;申培丽;王盼;: "岩藻多糖改善胃肠道功效研究进展", 食品与发酵科技, no. 06, 25 December 2019 (2019-12-25), pages 91 - 97 * |
| 宋海燕;何文辉;张泽华;袁荣荣;: "响应面法优化鹿角菜中岩藻多糖的超声波辅助提取工艺", 食品与发酵工业, no. 12, 31 December 2015 (2015-12-31) * |
| 杨远廷;舒绪刚;罗帆;吴紫倩;黄丽婷;田允波;: "岩藻多糖的生物学功能及其在动物生产中的应用", 仲恺农业工程学院学报, no. 02, 15 June 2020 (2020-06-15), pages 66 - 71 * |
| 赵美惠;詹麒平;戴宇峰;张昕;常耀光;王静凤;: "海地瓜岩藻聚糖硫酸酯抑制慢性低度炎症反应及机制研究", 中国海洋药物, no. 04, 15 August 2016 (2016-08-15) * |
| 马玉静;杨玲;何荣香;贺建华;: "岩藻多糖的生理功能及其在动物生产中的应用", 中国畜牧兽医, no. 08, 31 December 2020 (2020-12-31), pages 2404 - 2412 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deng et al. | Mechanism of the immunostimulatory activity by a polysaccharide from Dictyophora indusiata | |
| Deng et al. | Anti-tumor activity of the regenerated triple-helical polysaccharide from Dictyophora indusiata | |
| CN108546306B (en) | Cordyceps militaris culture medium polysaccharide, and separation and purification method and application thereof | |
| EP1044221A1 (en) | Novel pectic polysaccharides purified from angelica gigas nakai and purification method and use as immuno-stimulating agent thereof | |
| CN108164614B (en) | Preparation method of gelidium amansii polysaccharide with immunoregulation effect, structural part characterization and application thereof | |
| CN101250572B (en) | Method for extracting pig blood antibiotic peptide | |
| CN117343206A (en) | Preparation method of fucoidin and application of fucoidin in preparation of anti-inflammatory drugs | |
| CN107880143A (en) | A kind of new application in terms of the medicine preparation of Dendrobium officinale polysaccharide and its Reperfu- sion that resists myocardial ischemia | |
| US20230057861A1 (en) | Use of corydalis saxicola bunting and formulation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| PL209967B1 (en) | Polysaccharide of echinacea angustifolia | |
| CN115490780B (en) | Extraction method and application of crude extract of gulfweed fucoidin | |
| WO2023036203A1 (en) | Cs-4 fermented mycelium heteropolysaccharide, preparation method therefor and use thereof | |
| CN115160450B (en) | Rapid preparation method and application of Pholiota nameko polysaccharide | |
| CN1931181A (en) | New use of tremella heteropolysaccharide or its extract | |
| van Kammen | The occurrence of infectious virus ribonucleic acid in the ribosomal fraction from tobacco mosaic virus infected tobacco leaves | |
| CN112237588B (en) | Application of oyster mushroom polysaccharide selenoside-III anticancer active ingredient in preparation of medicine for resisting prostate cancer | |
| EP1443950A2 (en) | A plant extract active as an immunostimulating agent | |
| CN111150752A (en) | Application of abrus herb extract in preparing anticancer medicine | |
| CN113209362A (en) | Platelet-rich plasma biological preparation derived from umbilical cord blood for skin repair and preparation method and application thereof | |
| CN115181193B (en) | Preparation method and application of 'golden silkworm flower' anti-inflammatory active polysaccharide | |
| CN102488700A (en) | Application of sargassan to preparation of medicament for preventing and treating urinary calculus | |
| CN1513881A (en) | Lucid ganoderma spore powder polysaccharide, production method and use | |
| CN117247472B (en) | Fucoidin and preparation method and application thereof | |
| CN105727310B (en) | Based on chitosan package ALV-J P-miRNA-env recombinant plasmid nano-complex and its preparation method and application | |
| CN1398901A (en) | Prepn and use of curcuma oligosaccharide sulfate derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |